Get the latest news on HUTN stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on HUTN performance

Latest HUTN Stock News | OTC:HUTN | Benzinga

HUTN Inc is a non-operating holding company engages in the provision of B2C internet services. It sells and distribute their products and services to consumers through the internet and generates revenue from the subscription services.

News

Movers & Shakers

Intraday Update

Markets

Movers

Trading Ideas

General

ADAP

ADGO

AEYE

AIHS

ALEAFIA HEALTH INC ORD by Aleafia Health Inc.

ALEAF

ANDE

APEI

Adtalem Global Education Inc. Common Stock

ATGE

ATVK

AXAS

AXTI

BARRF

BBIO

BCDS

BIOL

BLFR

BRSWQ

BRTX

BTCS

BTLLF

CCAN

CCRC

CDEV

CELLCUBE ENERGY STORAGE by Cellcube Energy Storage Sys Inc.

CECBF

CELC

CGNSF

CHCX

CLVS

CMCT

CNONF

CNSL

COBALT BLOCKCHAIN INC by Cobalt Blockchain Inc.

COBCF

CRTPF

CRUUF

CRYCY

DKAM

DLOC

ELOX

EMESQ

EWLL

EZCL

FSDDF

FUAPF

GALXF

GEMP

GNFT

GNFTF

GRTD

HAON

HTBX

HUTN

INMB

IRNC

JAGX

KALV

KOIOS BEVERAGE CORP by Koios Beverage Corp.

KBEVF

LIVX

LRSNF

LRTTF

LTMCF

MAKSY

MAYS

MINE

MMMM

MORF

MRNJ

MARICANN GROUP INC ORD by Maricann Group Inc

MRRCF

MRSN

MYMMF

MYOV

NANX

NEOM

NMTC

NSPXD

NUGS

OMAG

PBBSF

PEYUF

PGPEF

PHMB

PNAT

PPSI

PRPM

PTAIF

RTIX

SCON

SLCA

SPLIF

Stocks That Hit 52-Week Lows Of Monday

HUTN Inc

Guidance

TGNA

TEGNA Sees FY25 Free Cash Flow Of $900M - $1.1B; Capital Expenditure Of $50M - $60M

Baird analyst Brian Skorney maintains Mirum Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRM#NASDAQ">MIRM</a>) with a Outperform and raises the price target from $50 to $55.

Price Target

Analyst Ratings

MIRM

Baird Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $55

The study is expected to randomize thirty-six (36) patients in four sites in UAE, which are Cleveland Clinic Abu Dhabi&nbsp;(CCAD), Sheikh Shakbout Medical City (SSMC), Burjeel Medical City (BMC), and American Hospital of Dubai (AHD).
 &nbsp;

MDCX

Medicus Pharma Submits Clinical Design (SKNJCT-004) To UAE DOH To Non-Invasively Treat BCC Of The Skin

Rosenblatt analyst Blair Abernethy maintains Synopsys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPS#NASDAQ">SNPS</a>) with a Buy and maintains $660 price target.

SNPS

Rosenblatt Maintains Buy on Synopsys, Maintains $660 Price Target

Baird analyst Joel Beatty maintains Cogent Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COGT#NASDAQ">COGT</a>) with a Neutral and lowers the price target from $10 to $8.

COGT

Baird Maintains Neutral on Cogent Biosciences, Lowers Price Target to $8

Health Care

Stock Split

VERO

Venus Concept Will Effect A 1-for-11 Reverse Stock Split, Effective At 5:00 P.M. Eastern Standard Time On March 3

Needham analyst David Saxon reiterates ZimVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZIMV#NASDAQ">ZIMV</a>) with a Buy and maintains $23 price target.

Reiteration

ZIMV

Needham Reiterates Buy on ZimVie, Maintains $23 Price Target

Dyne Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) reported quarterly losses of $(0.88) per share which beat the analyst consensus estimate of $(0.99) by 11.11 percent. This is a 19.27 percent increase over losses of $(1.09) per share from the same period last year.

Earnings

Earnings Beats

Dyne Therapeutics Q4 2024 GAAP EPS $(0.88) Beats $(0.99) Estimate

Baird analyst Jeff Johnson maintains Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) with a Outperform and raises the price target from $104 to $108.

Baird Maintains Outperform on Alcon, Raises Price Target to $108

Cars.com (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARS#NYSE">CARS</a>) reported quarterly earnings of $0.49 per share which missed the analyst consensus estimate of $0.56 by 12.5 percent. This is a 2.08 percent increase over earnings of $0.48 per share from the same period last year. The company reported quarterly sales of $180.43 million which missed the analyst consensus estimate of $183.90 million by 1.88 percent. This is a 0.46 percent increase over sales of $179.61 million the same period last year.

Earnings Misses

CARS

CORRECTION: Cars.com Q4 Adj EPS $0.49 Misses $0.56 Estimate, Sales $180.43M Miss $183.90M Estimate

Tegna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGNA#NYSE">TGNA</a>) reported quarterly earnings of $1.21 per share which beat the analyst consensus estimate of $1.16 by 4.31 percent. This is a 181.4 percent increase over earnings of $0.43 per share from the same period last year. The company reported quarterly sales of $870.53 million which missed the analyst consensus estimate of $870.79 million by 0.03 percent. This is a 19.93 percent increase over sales of $725.85 million the same period last year.

Tegna Q4 Adj $1.21 Beats $1.16 Estimate, Sales $870.53M Miss $870.79M Estimate

Rosenblatt analyst Blair Abernethy maintains Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Buy and maintains $205 price target.

SNOW

Rosenblatt Maintains Buy on Snowflake, Maintains $205 Price Target

Baird analyst Eric Coldwell maintains AdaptHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHCO#NASDAQ">AHCO</a>) with a Outperform and raises the price target from $14 to $16.

AHCO

Baird Maintains Outperform on AdaptHealth, Raises Price Target to $16

THRY

Thryv Sees Q1 SaaS Revenue Of $107.5M - $110.0M; SaaS Adjusted EBITDA Of $9.0M - $9.5M

Baird analyst Catherine Schulte maintains Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) with a Outperform and lowers the price target from $161 to $159.

Baird Maintains Outperform on Agilent Technologies, Lowers Price Target to $159

Cars.com Sees Q1 Revenues Between $178M-$181M; FY25 Revenues Are Expected Between $745M-$755M Vs. $757.68M Estimate

Thryv Sees FY25 SaaS Revenue Of $464.5M - $474.0M; SaaS Adjusted EBITDA Of $69.5M - $71.0M

Baird analyst Mark Altschwager maintains Urban Outfitters (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) with a Neutral and raises the price target from $60 to $62.

URBN

Baird Maintains Neutral on Urban Outfitters, Raises Price Target to $62

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/02/27072845/Luckin-0227.png" alt="" class="wp-image-6724" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/02/27072845/Luckin-0227.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/02/27072845/Luckin-0227-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/02/27072845/Luckin-0227-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The company strengthened its position as China's leading coffee chain in last year's fourth quarter, as Starbucks looked for a new way forward in the ultra-competitive market

<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul>
<li>Luckin reported strong triple-digit gains in its operating and net income in the fourth quarter, sparking an 8% rally in its shares</li>
<li>A weakened Starbucks is seeking a strategic partner for its $1 billion China business as consumers reject its pricey coffee in favor of cheap brews from its rivals</li>
</ul>
It was probably just a quirk of timing that&nbsp;Luckin Coffee Inc.&nbsp;(LKNCY.US) served up its&nbsp;<a href="https://www.globenewswire.com/news-release/2025/02/20/3029471/0/en/Luckin-Coffee-Announces-Fourth-Quarter-and-Fiscal-Year-2024-Financial-Results.html">latest quarterly results</a>&nbsp;on Feb. 20, a few weeks after local archrival&nbsp;Starbucks&nbsp;(SBUX.US) offered its own latest financial report card on Jan. 28. But the two reports were as different as black and white, as Luckin strengthened its position as leader of the overheated Chinese market while Starbucks remained in a state of disarray.
Luckin's fourth quarter earnings were nothing short of spectacular, following a rocky period for the company and its peers amid an ongoing price war. The company's revenue rose 36.1% year-over-year to 9.6 billion yuan ($1.3 billion) in last year's fourth quarter, while its operating income soared 368% to 995 million yuan, and net income rose 184% to 841 million yuan.
Its self-operated same-store sales continued to drop during the quarter, but the declines eased notably to down 3.4% from negative 13.1% in the previous quarter. CFO An Jing added to the positive news by saying the metric turned positive in December, ending three quarters of declines.
Investors applauded the report by bidding up Luckin shares by 8% the day of the announcement, though the stock gave back all those gains over the next four trading days.
Behind the numbers is a brutal competition for market share, as Luckin and chief low-cost rival&nbsp;Cotti Coffee&nbsp;have matched each other's aggressive price cuts over the past two years, both selling their premium brew for as little 9.9 yuan per cup. One of the biggest victims of those price wars has been Starbucks, which has largely stuck to its far higher premium prices.
Starbucks reported its revenue in China, its second-largest market after the U.S., rose by an anemic 1% to $743.6 million year-over-year in the final three months of last year. Its same-store China sales fell 6%, reversing a 10% increase a year earlier, while its average ticket fell by 4%, improving from a 9% decline a year earlier. Starbucks also said its transactions fell by 2% during the quarter, a sharp reversal from a 21% rise a year earlier, as China's increasingly cautious consumers opted for lower-cost options like Luckin and Cotti.
Starbucks hasn't exactly given up on China, despite the difficulties, and continues to open new stores. Its domestic store count of 7,685 at the end of last year was up by 10% from a year earlier, though that appears to be behind a previously announced goal of 9,000 stores by 2025. By comparison, Luckin had 22,340 stores as of the end of last year, up 37.5% year-on-year, which helps to explain its nearly identical revenue growth in the face of such fierce competition.
Starbucks isn't just sitting idly by as its China ship wobbles. Its longtime China chief left the company in January, and global CEO Brian Nicol confirmed he is looking for strategic partners to help turn the operation around. Companies mentioned as showing interest in the unit, which is valued at about $1 billion, include&nbsp;Meituan&nbsp;(3690.HK),&nbsp;China Resources&nbsp;and private equity firms&nbsp;PAG,&nbsp;KKR&nbsp;and&nbsp;FountainVest.
<h4 class="wp-block-heading">Coffee love affair</h4>
When Starbucks opened its first store in Beijing in 1999, it was the start of a love affair with barista-style coffee in a tea drinking nation. Fast forward to the end of 2024, when its China stores accounted for nearly a fifth of its global total, as Chinese millennials flocked to those stores as much for their upscale urban image as for its coffee.
But China's economic slowdown has changed all that, driving consumers to lower-cost options. Luckin and Cotti are catering to such coffee drinkers, with both recently indicating they have no plans to turn back the taps on the 9.9 yuan coffee wars.
Despite the intense competition, everyone is still eyeing a market with big growth potential. The market was worth an estimated $16 billion in 2025, only one-fifth the size of the U.S. at $90 billion, according to Statista, even though China's population is more than four times the U.S.
While Luckin is growing at lightning speed, Cotti, which was founded by Luckin's disgraced co-founders who left after a major accounting scandal, is growing even faster. Cotti has said it aims to have 50,000 stores by the end of 2025, partly by embedding its kiosks within other venues such as convenience stores and food and beverage outlets.
Cotti Chief Strategy Officer Li Yingbo said at a conference in November the company had lined up 50 retail partners for the initiative, including convenience store chain Meiyijia, fast-food operator Fujian Wallace Food Co. and budget hotel operator BTG Homeinns, with the potential to collectively add up to 100,000 new locations.
The company still has quite a bit of ground to cover to reach its 50,000-store goal. Last October it said it had 10,000 stores globally, 95% of those in China. But it reached that milestone just two years after opening its first store in Fuzhou, capital of Southern China's Fujian province.
Luckin's strategy includes investment in supply chain and production facilities to build up its operation, which is a combination of about two-thirds self-operated stores and one-third franchised. Last November, it signed a $1.38 billion agreement for the Brazilian Trade and Investment Promotion Agency to supply it with 240,000 metric tons of coffee over five years, an important hedge against rising coffee prices. Luckin also launched a new 570,000-square-foot roasting facility in the Eastern Chinese city of Suzhou last April and began construction of a new 3 billion yuan roastery and supply chain hub in Qingdao five months later.
Luckin has also announced international expansion plans, starting in Singapore, where it now has 51 stores. It had another two stores in Malaysia at the end of last year, and is reportedly eyeing the U.S. market, which would be a bold move into Starbucks' home turf.
Despite its consolidating position as China's coffee market leader, Luckin's valuation still looks lukewarm compared to Starbucks. It currently trades at a price-to-earnings (P/E) ratio of 24 and is valued at $8.4 billion, which are far cries from Starbucks' $130 billion market cap and P/E ratio of 37. Cotti is still a private company and is almost certainly still losing big money due to its aggressive tactics and early stage of development.
Dozens of analysts follow Starbucks, a proxy for the global consumer economy, while only four polled by Yahoo Finance follow Luckin, which withdrew its U.S. listing after the 2020 accounting scandal and now trades over-the-counter. But those analysts are betting heavily on the company. Of the three with ratings on Luckin, two give it a "buy" while the third gives it a "strong buy."

Asia

Restaurants

Exclusives

Starbucks' Struggle Vs. Luckin's Lead In China's Coffee Wars

Rosenblatt analyst Blair Abernethy maintains Bentley Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSY#NASDAQ">BSY</a>) with a Buy and maintains $62 price target.

Rosenblatt Maintains Buy on Bentley Systems, Maintains $62 Price Target

Comments

HUTN Stock News

News

Latest HUTN Stock News | OTC:HUTN | Benzinga

Monday, October 07, 2019

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga